Skip to content

Risankizumab

Interleukin-23 Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: 655066-01, ABBV-066, BI-655066, BI655066, risankizumab (genetical recombination), risankizumab-rzaa, skyrizi

EMA approvedFDA approvedPMDA approvedATC L04AC18

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Risankizumab is a drug in the Interleukin-23 Antagonist class catalogued in DrugCentral. It was first approved by the PMDA in 2019. Its mechanism of action is classified as Interleukin-23 Antagonists. DrugCentral lists 1 molecular target, including IL23A. Recorded indications include Crohn's disease, Erythrodermic psoriasis, Palmoplantar pustulosis and Plaque psoriasis.

  • Drug class: Interleukin-23 Antagonist.
  • Mechanism of action: Interleukin-23 Antagonists.
  • Molecular targets: IL23A (1 listed in DrugCentral).
  • Indications: Crohn's disease, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis and Psoriasis and others.
  • ATC code: L04AC18 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

  • Crohn's disease
  • Erythrodermic psoriasis
  • Palmoplantar pustulosis
  • Plaque psoriasis
  • Psoriasis
  • Psoriatic arthritis
  • Pustular psoriasis

Mechanism & targets

Mechanism of action (MoA)Interleukin-23 Antagonists
Established pharmacologic classInterleukin-23 Antagonist

Molecular targets (1)

TargetGeneActionActivity
Interleukin-23 subunit alphaIL23AinhibitorKd 11.00

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2019-04-26EMA—AbbVie Deutschland GmbH & Co KG
2019-04-23FDA—AbbVie INC
2019-03-26PMDA—AbbVie Deutschland GmbH & Co KG

ATC classification

ATC codeTherapeutic hierarchy
L04AC18ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Product storage error750.7
COVID-19290.2
Surgery265.2
Ileocaecal resection253.7
Product temperature excursion issue251.7
Death242.1
Psoriasis235.7
Drug ineffective193.3
Intestinal obstruction186.4
Therapy interrupted181.4
Ileostomy169.1
Ileal stenosis167.6

Chemical structure

Molecular formula—
Molecular weight—
CAS number1612838-76-2
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Risankizumab used for?

DrugCentral lists the following indications for Risankizumab: Crohn's disease, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriasis, Psoriatic arthritis and Pustular psoriasis.

How does Risankizumab work?

Risankizumab is classified as Interleukin-23 Antagonists; its molecular targets in DrugCentral include IL23A (inhibitor).

When was Risankizumab first approved?

Risankizumab was first approved by the PMDA in 2019.

What drug class does Risankizumab belong to?

Risankizumab is in the Interleukin-23 Antagonist class.

Browse: all drugs starting with R · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2019-03-26
AgencyPMDA
Targets1
Indications7
Formula—
DrugCentral ID5337
Interactive profile